Not currently recruiting at University of California Health
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
- Principal Investigator
- by John Shen (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- John Shen (ucla)
HS Assistant Clinical Professor, Medicine
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- ID
- NCT05288166
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 900 study participants
- Last Updated